2008;29:1681 7. S4.4.2-21. Goldberg DJ, French B, McBride MG, et al. Impact of oral silden- afil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-con- trolled, crossover trial. Circulation. 2011;123:1185 93. CLINICAL STATEMENTS AND GUIDELINES S4.4.2-22. Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19: 331 9. S4.4.2-23. Bowater SE, Weaver RA, Thorne SA, et al. The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis. 2012;7:243 9. S4.4.2-24. Derk G, Houser L, Miner P, et al. Efficacy of endothelin blockade in adults with Fontan physiology. Congenit Heart Dis. 2015;10:E11 6. S4.4.2-25. Schuuring MJ, Vis JC, van Dijk APJ, et al. Impact of bosentan on ex- ercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690 8. S4.4.2-26. Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. Int J Cardiol. 2013;168:3940 3. S4.4.2-27. Harper AR, Crossland DS, Perri G, et al. Is alternative cardiac sur- gery an option in adults with congenital heart disease referred for thoracic organ transplantation? Eur J Cardiothorac Surg. 2013;43:344 51. S4.4.2-28. John AS, Driscoll DJ, Warnes CA, et al. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2011;92:1451 6. S4.4.2-29. Schumacher KR, Cools M, Goldstein BH, et al. Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients. Pediatr Cardiol. 2011;32:966 71. S4.4.2-30. John AS, Phillips SD, Driscoll DJ, et al. The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation. Congenit Heart Dis. 2011;6:653 6. S4.4.2-31. 